Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
Takeda Pharmaceutical is weighing an increase in imports of one of its plasma-derived immunoglobulin products to offset a domestic supply shortfall following the suspension of another therapy, the company told Jiho on November 4. The company said it might raise…
To read the full story
Related Article
- Takeda Rolls Out Higher-Concentration Kenketu Glovenin-I 10%
July 7, 2026
- Takeda to Shift Immunoglobulin Production to 10% Formulation
June 29, 2026
- Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
February 12, 2026
- Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
December 25, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
BUSINESS
- FDA Accepts BridgeBio’s Infigratinib NDA for Achondroplasia
October 8, 2026
- Eylea 8 mg Shows Vision Gains in 24-Week Analysis
October 8, 2026
- Boehringer, Hiroshima Tie Up on Health Promotion
October 8, 2026
- Japan Ethical Drug Sales Up 3% in August: Crecon
October 8, 2026
- PeptiDream Earns Milestone Payment from US Merck
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…